These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 17935224)

  • 1. Hepatitis C virus kinetics in chimeric mice during antiviral therapy.
    Dahari H; Perelson AS
    Hepatology; 2007 Dec; 46(6):2048-9; author reply 2049-50. PubMed ID: 17935224
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to issues raised in the Jansen/Reesink editorial.
    Silva M
    J Hepatol; 2007 Feb; 46(2):350-1. PubMed ID: 17161883
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetic and pharmacodynamic modeling of pegylated-interferon alfa.
    Dimova RB; Talal AH
    J Hepatol; 2010 Sep; 53(3):418-20. PubMed ID: 20561707
    [No Abstract]   [Full Text] [Related]  

  • 4. Novel therapies in Hepatitis C virus. Preface.
    Pockros PJ
    Clin Liver Dis; 2009 Aug; 13(3):xiii. PubMed ID: 19628152
    [No Abstract]   [Full Text] [Related]  

  • 5. Pegylated interferons.
    Karnam US; Reddy KR
    Clin Liver Dis; 2003 Feb; 7(1):139-48. PubMed ID: 12691463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus therapy to date.
    Foster G; Mathurin P
    Antivir Ther; 2008; 13 Suppl 1():3-8. PubMed ID: 18432157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peginterferon alfa-2b vs. peginterferon alfa-2a in the treatment of hepatitis C, is there any difference?
    Sierra F
    J Hepatol; 2007 Feb; 46(2):349; author reply 349-50. PubMed ID: 17161495
    [No Abstract]   [Full Text] [Related]  

  • 8. Peginterferons in hepatitis C virus: virological, pharmacokinetic, and clinical implications. Introduction.
    Keeffe EB
    Semin Liver Dis; 2003; 23 Suppl 1():1-2. PubMed ID: 12934161
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful pegylated interferon alpha2a monotherapy for hepatitis C virus infection in a transplanted patient who relapsed after the preceding course.
    Ichikawa T; Taura N; Miyaaki H; Matsuzaki M; Eguchi S; Takatsuki M; Kanematsu T; Nakao K
    Transpl Infect Dis; 2011 Aug; 13(4):438-40. PubMed ID: 21309967
    [No Abstract]   [Full Text] [Related]  

  • 10. [Assessment and monitoring of patients with chronic hepatitis C on antiviral therapy--state of the art in 2003].
    Simon K; Szymczak A
    Pol Arch Med Wewn; 2004 Jul; 112(1):891-8. PubMed ID: 15526854
    [No Abstract]   [Full Text] [Related]  

  • 11. [Successful therapy with pegylated interferon alfa-2a. Hepatitis C patients remain virus-free].
    MMW Fortschr Med; 2003 Sep; 145(35-36):56. PubMed ID: 14584218
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of acute hepatitis C-how to explain the differences?
    Wedemeyer H; Cornberg M; Wiegand J; Jäckel E; Manns MP
    Gastroenterology; 2006 Aug; 131(2):682-3; author reply 683-4. PubMed ID: 16890627
    [No Abstract]   [Full Text] [Related]  

  • 13. A perspective on modelling hepatitis C virus infection.
    Guedj J; Rong L; Dahari H; Perelson AS
    J Viral Hepat; 2010 Dec; 17(12):825-33. PubMed ID: 20723038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling HCV kinetics under therapy using PK and PD information.
    Shudo E; Ribeiro RM; Perelson AS
    Expert Opin Drug Metab Toxicol; 2009 Mar; 5(3):321-32. PubMed ID: 19331594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Genotype 1 superresponder treat for only 24 weeks].
    MMW Fortschr Med; 2005 Dec; 147(51-52):69. PubMed ID: 16402717
    [No Abstract]   [Full Text] [Related]  

  • 16. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics.
    Kamal SM; Ismail A; Graham CS; He Q; Rasenack JW; Peters T; Tawil AA; Fehr JJ; Khalifa Kel S; Madwar MM; Koziel MJ
    Hepatology; 2004 Jun; 39(6):1721-31. PubMed ID: 15185314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response.
    Malnick SD; Basevitch A
    Gastroenterology; 2006 Aug; 131(2):683; author reply 683-4. PubMed ID: 16890628
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo.
    Inoue K; Umehara T; Ruegg UT; Yasui F; Watanabe T; Yasuda H; Dumont JM; Scalfaro P; Yoshiba M; Kohara M
    Hepatology; 2007 Apr; 45(4):921-8. PubMed ID: 17393519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interfering with interferon: re-igniting the debate on calcineurin inhibitor choice and antiviral therapy for hepatitis C virus recurrence.
    Watashi K; Metselaar HJ; van der Laan LJ
    Liver Transpl; 2008 Mar; 14(3):265-7. PubMed ID: 18306373
    [No Abstract]   [Full Text] [Related]  

  • 20. Peginterferon alfa-2a (Pegasys) for chronic hepatitis C.
    Med Lett Drugs Ther; 2003 Mar; 45(1151):19-20. PubMed ID: 12612502
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.